Treatment of Stage IV of Esophageal Cancer

Cancer Connect

Medically reviewed by C.H. Weaver M.D. 9/2020

Patients with stage IV esophageal cancer have metastatic cancer that has spread to distant sites. Optimal treatment of patients with stage IV esophageal cancer often requires more than one therapeutic approach. Thus, it is important for patients to be treated at a medical center that can offer multi-modality treatment involving medical oncologists, radiation oncologists, surgeons, gastroenterologists and nutritionists. Treatment approaches are primarily directed at controlling the symptoms of cancer and prolonging survival. A number of treatment options are currently utilized alone or in combination to achieve optimal results.

Current research suggests that combining immunotherapy with chemotherapy can reduced the risk of death by 27% compared to chemotherapy when used as the initial treatment of esophageal cancer. In addition there are specific treatments that can be administered that can result in short-term benefit and improvement in nutrition. (1)

About Checkpoint Inhibitors

Keytruda and Opdivo (nivolumab) belong to a class of medicines called “checkpoint inhibitors.” Checkpoint inhibitors are a novel precision cancer immunotherapy that helps to restore the body’s immune system in fighting cancer by releasing checkpoints that cancer uses to shut down the immune system. PD-1 and PD-L1 are proteins that inhibit certain types of immune responses, allowing cancer cells to evade detection and attack by certain immune cells in the body. A checkpoint inhibitor can block the PD-1 and PD-L1 pathway and enhance the ability of the immune system to fight cancer. By blocking the binding of the PD-L1 ligand these drugs restore an immune cells’ ability to recognize and fight the colon cancer cells. A diagnostic test to measure the level of PD-L1 is available.

Data from Phase 3 trials evaluating checkpoint inhibitors in combination with platinum-based chemotherapy for the first-line treatment of patients with locally advanced or metastatic esophageal and gastroesophageal junction (GEJ) cancer was featured during a Presidential Symposium at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 on Monday, Sept. 21

The study found that checkpoint inhibitor immunotherapy when combined with chemotherapy improved the response to treatment, delayed cancer progression, and prolonged survival.

About KEYNOTE-590

KEYNOTE-590 is a Phase 3, randomized, double-blind clinical trial that enrolled 749 patients with locally advanced or metastatic esophageal carcinoma (including esophageal squamous cell carcinoma and adenocarcinoma of the esophagus) to compare treatment with Keytruda in combination with chemotherapy or chemotherapy alone regardless of histology or PD-L1 expression status.

At the first interim analysis, after a median follow-up of 10.8 months, Keytruda in combination with chemotherapy

  • Produced an overall response to treatment of 45% versus 29.3% for chemotherapy.
  • Demonstrated superior survival - the median survival duration was 12.4 months in the Keytruda combination arm versus 9.8 months for chemotherapy. In patients with ESCC whose tumors expressed PD-L1 (CPS ≥10), the median OS was 13.9 months in the Keytruda combination arm versus 8.8 months for chemotherapy alone.
  • Delayed cancer progression reducing the risk of disease progression or death by 35% or more than a third.
  • Treatment-related side effects led to discontinuation of treatment in 19.5% of patients in the Keytruda combination arm and 11.6% of patients in the chemotherapy arm.

About CheckMate -649

Checkmate-649 compared Opdivo plus chemotherapy and Opdivo plus Yervoy (ipilimumab) to chemotherapy alone as the initial treatment for patients with previously untreated, non-HER2-positive, advanced or metastatic gastric cancer, GEJ cancer or esophageal adenocarcinoma in patients with a combined positive score (CPS) ≥ 5. The median survival duration was 14.4 months compared to 11.1 months for chemotherapy alone among PD-L1 positive patients with CPS ≥ 5. (2)

Surgery for Palliation

Patients with stage IV esophageal cancer often have widespread cancer at the time of diagnosis and cannot be cured with surgery. There is controversy over how best to treat patients who cannot undergo surgery with curative intent. In one clinical study, doctors compared the outcomes of 39 patients with stage IV esophageal cancer who underwent an esophagectomy for palliation with the outcomes of 49 patients with stage IV esophageal cancer who underwent more complete removal of cancer. Both groups of patients experienced significant improvement with regard to both the quantity and quality of food intake and a reduction in the severity of eating related symptoms. After 9 months, patients in the palliative group experienced more pain and a poorer quality of life, but there were no differences in sleep, leisure activity and performance scores when compared to the other group. This study suggests that palliative esophagectomy relieves symptoms in the majority of patients with inoperable esophageal cancer. It could also be argued that both groups had palliative surgery since the majority of patients who undergo surgery with curative intent have rapid recurrence of cancer in the first year or two after surgery.

To learn more, go to Surgery and Cancer of the Esophagus.

Chemotherapy

Single chemotherapy drugs such as the taxanes (paclitaxel and Taxotere®) may be the most active single chemotherapy drugs for the treatment of esophageal cancer, with complete remissions occurring in up to 15% of patients. Platinol®, fluorouracil, Mutamycin®, doxorubicin, and Ellence® can also result in clinical remissions in patients with esophageal cancer. Historically, standard chemotherapy treatment regimens often utilized Platinol®, flourouracil and Ellence® or Mutamycin®. The overall response rate for these combination regimens is approximately 40% and the average survival duration is 8-10 months. Other agents that have been or are being evaluated include Camptosar® and Gemzar®. All current clinical trials involve various combinations of drugs.

Currently available combination chemotherapy treatment for stage IV cancer results in complete remission in up to 20% of patients, with average survival of 8-12 months. As newer drugs, such as the taxanes, Camptosar®, and Gemzar®, are incorporated into regimens, this may continue to improve.

Other Treatment Modalities

Many other treatment modalities are utilized to prolong survival and quality of life for patients with esophageal cancer.

Thermal laser: Thermal laser coagulation performed by endoscopy can provide temporary relief of dysphagia. Laser ablation appears to be most helpful for treating polypoid cancers that grow into the esophagus causing occlusion. Laser treatment is less effective for upper esophageal cancers or cancers of the gastroesophageal junction. A multi-center clinical trial has compared photodynamic laser therapy to thermal laser ablation for the palliation of patients with esophageal cancer who experience difficulty swallowing food. In general, photodynamic laser therapy was more effective than thermal laser treatment.

Photodynamic treatment: Photodynamic ablation has been used for the palliation of patients with esophageal cancer. Photodynamic treatment involves injection of a light sensitizer into a vein, which is then taken up by cells. A laser is then directed at the cancer cells. The reaction between the laser and the light sensitizer destroys the cells. The objective response rate at one month with this approach has been reported to be 32% for patients receiving photodynamic laser treatment, which compared favorably to the 20% reported for patients receiving thermal-laser treatment.

Esophageal dilatation: Frequently, after the administration of chemotherapy, radiation therapy, laser or photodynamic treatment, the area of the esophagus with cancer can be constricted or narrowed. Narrowing of the esophagus may be due to recurrent cancer or to treatment induced strictures or both. Relief of this constriction by dilation can temporarily improve swallowing. During esophageal dilation, a physician uses endoscopic or fluoroscopic guidance to pass flexible dilators (mercury filled rubber tubes) through the mouth. Increasing diameters of dilators, called bougies, are gradually introduced until the difficulty in swallowing resolves. One clinical study reported a 92% success rate for dilation. The duration of symptom relief after successful dilatation varies from days to weeks. One complication of esophageal dilation is the potential for perforation; however, this occurs only rarely. In a large study of 154 patients, a total of 3,140 dilators were passed before, during and after radiation therapy and resulted in only two perforations.

Esophageal stents or prostheses: Stents are rigid tubes that stay in the esophagus to keep it open. Recently, a clinical study evaluated the use of esophageal stents over a 4-year period for the management of patients with inoperable esophageal cancer. In a group of 160 patients with esophageal cancer,159 had stents placed successfully. In this study, a traditional rigid tube was placed in 84 patients and metallic self-expanding stents were placed in 75 patients. After placement of the stents, chemotherapy and/or radiation therapy was administered to 82 patients. The results indicated that 11% of patients had complications, including displacement of the stent, incomplete expansion of the stent, perforation of the esophagus or bleeding. Swallowing was improved in 97% of patients. These doctors concluded that placement of stents to improve swallowing was a relatively safe palliative procedure. Self-expanding metallic stents were thought to be preferable to rigid stents for maintaining an open esophagus.

Strategies to Improve Treatment

The progress that has been made in the treatment of esophageal cancer has resulted from improved patient and physician participation in clinical studies. Future progress in the treatment of esophageal cancer will result from continued participation in appropriate studies. Currently, there are several areas of active exploration aimed at improving the treatment of esophageal cancer.

New Chemotherapy Regimens: Development of new multi-drug chemotherapy treatment regimens that incorporate new or additional anti-cancer therapies is an active area of clinical research carried out in phase II clinical trials. These studies are performed in patients with stage IV or recurrent esophageal cancer.

Phase I Trials: New chemotherapy drugs or other anti-cancer therapies continue to be developed and evaluated in phase I clinical trials. The purpose of phase I trials is to evaluate new therapies in order to determine the best way of administering the drug and to determine whether the drug has any anti-cancer activity in patients with esophageal cancer. Patients with stage IV esophageal cancer should consider participation in phase I trials.

References:

  1. https://www.businesswire.com/news/home/20200902005293/en/New-Scientific-Data-ESMO-Virtual-Congress-2020, Abstract #LBA51
  2. Presentation #LBA6_PR - featured in a Presidential Symposium at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 on September 21 from 18:30-18:42 CEST.
Comments

Esophageal

FEATURED
COMMUNITY